Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca obtains FDA complete response letter for asthma drug
The FDA has stated that AstraZeneca did not provide adequate data to establish the appropriate dose or doses of the individual components of Symbicort – budesonide and formoterol
The FDA has stated that AstraZeneca did not provide adequate data to establish the appropriate dose or doses of the individual components of Symbicort – budesonide and formoterol
Through this partnership, BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten drug discovery timelines. This agreement is an
The agreement includes joint work in support of potential remedies and to identify effective ways to provide information and education to medical professionals and patients globally. The University
The Altropane Phase III program, called Poet-2, is designed to confirm the diagnostic utility of Altropane in anticipation of drug registration, and includes two, parallel clinical studies enrolling
Impax has filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Renvela with the FDA. Following receipt of the notice
With this move, Covance will build strategic relationships with investigators, sites, and regulatory authorities in a region known for its potential to contribute to high-quality global clinical trial
Ms Hagerty succeeds Lawrence Dolin, co-founder of Noteworthy. Mr Dolin will continue to serve on the board of directors and work with the company as a consultant. Ms
Mr Broek is founder and managing partner of HSMR Advisors, a US-based fund manager with an investment emphasis on small and mid-cap biotech public companies. During his career
Before Humana, Lord was president of Health Dialog in Boston, where he helped pioneer e-enabled health care. He has also served as chief operating officer of the American
SARcode, a biopharmaceutical company, has announced the results of its Phase I randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of